Actinium Pharmaceuticals to Participate in American Society for Blood and Marrow Transplantation 2017 Corporate Council Meeting
20 sept. 2017 07h30 HE
|
Actinium Pharmaceuticals
- Actinium is now a member of the ASBMT™ Corporate Council - Two day event focused on facilitating dialogue aimed at advancing the field of bone marrow transplantation and cellular therapy NEW YORK,...
Actinium Pharmaceuticals Highlights Presence at the Society of Hematologic Oncology 2017 Annual Meeting
13 sept. 2017 07h30 HE
|
Actinium Pharmaceuticals
- Company’s Actimab-A and Actimab-M programs to be presented at the conference NEW YORK, Sept. 13, 2017 (GLOBE NEWSWIRE) -- Actinium Pharmaceuticals, Inc (NYSE American:ATNM) (“Actinium” or “the...
Actinium to Present at The Rodman & Renshaw 19th Annual Global Investment Conference
06 sept. 2017 16h05 HE
|
Actinium Pharmaceuticals
NEW YORK, Sept. 06, 2017 (GLOBE NEWSWIRE) -- Actinium Pharmaceuticals, Inc. (NYSE American:ATNM) ("Actinium" or "the Company"), a biopharmaceutical company developing innovative targeted therapies...
Actinium Announces Closing of Public Offering of Common Stock and Warrants to Purchase Common Stock
02 août 2017 16h05 HE
|
Actinium Pharmaceuticals
Actinium raised total gross proceeds of $16.125 million NEW YORK, Aug. 02, 2017 (GLOBE NEWSWIRE) -- Actinium Pharmaceuticals, Inc. (NYSE American:ATNM) ("Actinium" or "the Company"), a...
Actinium Announces Pricing of Public Offering of Common Stock and Warrants to Purchase Common Stock
28 juil. 2017 09h10 HE
|
Actinium Pharmaceuticals
NEW YORK, July 28, 2017 (GLOBE NEWSWIRE) -- Actinium Pharmaceuticals, Inc. (NYSE MKT:ATNM) ("Actinium" or "the Company"), a biopharmaceutical company developing innovative targeted therapies for...
Actinium Announces Proposed Public Offering of Common Stock and Warrants to Purchase Stock
27 juil. 2017 16h05 HE
|
Actinium Pharmaceuticals
NEW YORK, July 27, 2017 (GLOBE NEWSWIRE) -- Actinium Pharmaceuticals, Inc. (NYSE MKT:ATNM) ("Actinium" or "the Company"), a biopharmaceutical company developing innovative targeted therapies for...
Actinium Pharmaceuticals Highlights Presence at Upcoming Society of Nuclear Medicine and Molecular Imaging Annual Meeting
08 juin 2017 07h30 HE
|
Actinium Pharmaceuticals
- Society of Nuclear Medicine and Molecular Imaging to be held June 10 – 14, 2017 in Denver, Colorado - Actinium to conduct webinar to provide an update on its Pivotal Phase 3 drug...
Actinium Pharmaceuticals Appoints Pharmaceutical Industry Executive Ajit S. Shetty, Ph.D., to the Company’s Board of Directors
28 mars 2017 07h00 HE
|
Actinium Pharmaceuticals
- Proven leader with 36 years of experience with Johnson & Johnson in numerous executive capacities, most recently as Head of Enterprise Supply Chain- Dr. Shetty was instrumental in establishing...
Actinium Pharmaceuticals to Present at 29th Annual ROTH Conference
07 mars 2017 07h00 HE
|
Actinium Pharmaceuticals
NEW YORK, March 07, 2017 (GLOBE NEWSWIRE) -- Actinium Pharmaceuticals, Inc. (NYSE MKT:ATNM) ("Actinium" or "the Company"), a biopharmaceutical company developing innovative targeted therapies...
Actinium Announces Expansion of Intellectual Property Portfolio with Notice of Allowance for U.S. Patent Related to Actimab-A, Actimab-M and the Company’s Technology Platform
28 févr. 2017 07h00 HE
|
Actinium Pharmaceuticals
Allowed patent application claims methods for generating radioimmunoconjugates linked to Actinium-225 Patent expected to expire in July 2030 NEW YORK, Feb. 28, 2017 (GLOBE NEWSWIRE) --...